A citation-based method for searching scientific literature

Cathelijne H van der Wouden, Ellen Paasman, Martina Teichert, Matty R Crone, Henk-Jan Guchelaar, Jesse J Swen. J Clin Med 2020
Times Cited: 7







List of co-cited articles
24 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Emerging roles for pharmacists in clinical implementation of pharmacogenomics.
Aniwaa Owusu-Obeng, Kristin W Weitzel, Randy C Hatton, Benjamin J Staley, Jennifer Ashton, Rhonda M Cooper-Dehoff, Julie A Johnson. Pharmacotherapy 2014
79
42


Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.
Seth Hetherington, Arlene R Hughes, Michael Mosteller, Denise Shortino, Katherine L Baker, William Spreen, Eric Lai, Kirstie Davies, Abigail Handley, David J Dow,[...]. Lancet 2002
562
28

HLA-B*5701 screening for hypersensitivity to abacavir.
Simon Mallal, Elizabeth Phillips, Giampiero Carosi, Jean-Michel Molina, Cassy Workman, Janez Tomazic, Eva Jägel-Guedes, Sorin Rugina, Oleg Kozyrev, Juan Flores Cid,[...]. N Engl J Med 2008
28


Knowledge, Attitude, and Perceptions of Pharmacists and Pharmacy Students towards Pharmacogenomics in Zimbabwe.
Nyasha Muzoriana, Samuel Gavi, Victoria Nembaware, Milcah Dhoro, Alice Matimba. Pharmacy (Basel) 2017
19
28


Assessment of the pharmacogenomics educational needs of pharmacists.
Kristen B McCullough, Christine M Formea, Kevin D Berg, Julianna A Burzynski, Julie L Cunningham, Narith N Ou, Maria I Rudis, Joanna L Stollings, Wayne T Nicholson. Am J Pharm Educ 2011
120
28

Attitudes of clinicians following large-scale pharmacogenomics implementation.
J F Peterson, J R Field, Y Shi, J S Schildcrout, J C Denny, T L McGregor, S L Van Driest, J M Pulley, I M Lubin, M Laposata,[...]. Pharmacogenomics J 2016
49
28

Pharmacogenetics: from bench to byte.
J J Swen, I Wilting, A L de Goede, L Grandia, H Mulder, D J Touw, A de Boer, J M H Conemans, T C G Egberts, O H Klungel,[...]. Clin Pharmacol Ther 2008
154
28

Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey.
E J Stanek, C L Sanders, K A Johansen Taber, M Khalid, A Patel, R R Verbrugge, B C Agatep, R E Aubert, R S Epstein, F W Frueh. Clin Pharmacol Ther 2012
271
28

Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers.
Henry M Dunnenberger, Kristine R Crews, James M Hoffman, Kelly E Caudle, Ulrich Broeckel, Scott C Howard, Robert J Hunkler, Teri E Klein, William E Evans, Mary V Relling. Annu Rev Pharmacol Toxicol 2015
262
28

Primary care providers' use of pharmacist support for delivery of pharmacogenetic testing.
Susanne B Haga, Rachel Mills, Jivan Moaddeb, Nancy Allen LaPointe, Alex Cho, Geoffrey S Ginsburg. Pharmacogenomics 2017
14
28

Implementing pharmacogenetic testing in rural primary care practices: a pilot feasibility study.
Lynn G Dressler, Gillian C Bell, Pearl M Abernathy, Karl Ruch, Sheri Denslow. Pharmacogenomics 2019
5
40

Integrating pharmacogenomics into electronic health records with clinical decision support.
J Kevin Hicks, Henry M Dunnenberger, Karl F Gumpper, Cyrine E Haidar, James M Hoffman. Am J Health Syst Pharm 2016
67
28

Education and Knowledge in Pharmacogenomics: Still a Challenge?
Jyothsna Giri, Timothy B Curry, Christine M Formea, Wayne T Nicholson, Carolyn R Rohrer Vitek. Clin Pharmacol Ther 2018
23
28

A pilot study of the implementation of pharmacogenomic pharmacist initiated pre-emptive testing in primary care.
Paul C D Bank, Jesse J Swen, Rowena D Schaap, Daniëlle B Klootwijk, Renée Baak-Pablo, Henk-Jan Guchelaar. Eur J Hum Genet 2019
21
28

Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact.
Cathelijne H van der Wouden, Paul C D Bank, Kübra Özokcu, Jesse J Swen, Henk-Jan Guchelaar. Genes (Basel) 2019
27
28

Pharmacogenomics in the clinic.
Mary V Relling, William E Evans. Nature 2015
371
28

Primary care physicians' knowledge of and experience with pharmacogenetic testing.
S B Haga, W Burke, G S Ginsburg, R Mills, R Agans. Clin Genet 2012
162
28



Implementation of a multidisciplinary pharmacogenomics clinic in a community health system.
Henry M Dunnenberger, Matthew Biszewski, Gillian C Bell, Annette Sereika, Holley May, Samuel G Johnson, Peter J Hulick, Janardan Khandekar. Am J Health Syst Pharm 2016
55
28

The Innovative Canadian Pharmacogenomic Screening Initiative in Community Pharmacy (ICANPIC) study.
John Papastergiou, Peter Tolios, Wilson Li, Jane Li. J Am Pharm Assoc (2003) 2017
18
28

Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?
M Verbelen, M E Weale, C M Lewis. Pharmacogenomics J 2017
97
14

Origins, admixture and founder lineages in European Roma.
Begoña Martínez-Cruz, Isabel Mendizabal, Christine Harmant, Rosario de Pablo, Mihai Ioana, Dora Angelicheva, Anastasia Kouvatsi, Halyna Makukh, Mihai G Netea, Horolma Pamjav,[...]. Eur J Hum Genet 2016
24
14

Requirements for comprehensive pharmacogenetic genotyping platforms.
Volker M Lauschke, Magnus Ingelman-Sundberg. Pharmacogenomics 2016
28
14

Application of Economic Evaluation to Assess Feasibility for Reimbursement of Genomic Testing as Part of Personalized Medicine Interventions.
Stavros Simeonidis, Stefania Koutsilieri, Athanassios Vozikis, David N Cooper, Christina Mitropoulou, George P Patrinos. Front Pharmacol 2019
8
14

Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant.
Annalise M Martin, David Nolan, Silvana Gaudieri, Coral Ann Almeida, Richard Nolan, Ian James, Filipa Carvalho, Elizabeth Phillips, Frank T Christiansen, Anthony W Purcell,[...]. Proc Natl Acad Sci U S A 2004
327
14

Allopurinol Use and Risk of Fatal Hypersensitivity Reactions: A Nationwide Population-Based Study in Taiwan.
Chien-Yi Yang, Chi-Hua Chen, Shin-Tarng Deng, Chi-Shan Huang, Yu-Jr Lin, Yi-Ju Chen, Chun-Ying Wu, Shuen-Iu Hung, Wen-Hung Chung. JAMA Intern Med 2015
97
14

Are whole-exome and whole-genome sequencing approaches cost-effective? A systematic review of the literature.
Katharina Schwarze, James Buchanan, Jenny C Taylor, Sarah Wordsworth. Genet Med 2018
190
14

The NICE cost-effectiveness threshold: what it is and what that means.
Christopher McCabe, Karl Claxton, Anthony J Culyer. Pharmacoeconomics 2008
436
14

Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
S Staszewski, P Keiser, J Montaner, F Raffi, J Gathe, V Brotas, C Hicks, S M Hammer, D Cooper, M Johnson,[...]. JAMA 2001
236
14

On the Estimation of the Cost-Effectiveness Threshold: Why, What, How?
Laura Vallejo-Torres, Borja García-Lorenzo, Iván Castilla, Cristina Valcárcel-Nazco, Lidia García-Pérez, Renata Linertová, Elena Polentinos-Castro, Pedro Serrano-Aguilar. Value Health 2016
66
14

Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout.
Catrin O Plumpton, Ana Alfirevic, Munir Pirmohamed, Dyfrig A Hughes. Rheumatology (Oxford) 2017
25
14

The cost-effectiveness of HLA-B*5801 screening to guide initial urate-lowering therapy for gout in the United States.
Eric Jutkowitz, Maureen Dubreuil, Na Lu, Karen M Kuntz, Hyon K Choi. Semin Arthritis Rheum 2017
37
14

Idiosyncratic adverse drug reactions: current concepts.
Jack Uetrecht, Dean J Naisbitt. Pharmacol Rev 2013
161
14

Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory.
Christina L Aquilante, Maximilian T Lobmeyer, Taimour Y Langaee, Julie A Johnson. Pharmacotherapy 2004
34
14

Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.
Ratchadaporn Somkrua, Elizabeth E Eickman, Surasak Saokaew, Manupat Lohitnavy, Nathorn Chaiyakunapruk. BMC Med Genet 2011
123
14

Economic Evaluations of Pharmacogenetic and Pharmacogenomic Screening Tests: A Systematic Review. Second Update of the Literature.
Elizabeth J J Berm, Margot de Looff, Bob Wilffert, Cornelis Boersma, Lieven Annemans, Stefan Vegter, Job F M van Boven, Maarten J Postma. PLoS One 2016
52
14

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Kimberly Y Smith, Parul Patel, Derek Fine, Nicholaos Bellos, Louis Sloan, Philip Lackey, Princy N Kumar, Denise H Sutherland-Phillips, Cindy Vavro, Linda Yau,[...]. AIDS 2009
166
14

The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application.
Manuel A Espinoza, Andrea Manca, Karl Claxton, Mark J Sculpher. Med Decis Making 2014
45
14

High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients.
Michael Saag, Rukmini Balu, Elizabeth Phillips, Philip Brachman, Claudia Martorell, William Burman, Britt Stancil, Michael Mosteller, Cindy Brothers, Paul Wannamaker,[...]. Clin Infect Dis 2008
263
14

Classifying ADRs--does dose matter?
Elizabeth J Phillips. Br J Clin Pharmacol 2016
22
14


Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations.
Faviel F González-Galarza, Louise Y C Takeshita, Eduardo J M Santos, Felicity Kempson, Maria Helena Thomaz Maia, Andrea Luciana Soares da Silva, André Luiz Teles e Silva, Gurpreet S Ghattaoraya, Ana Alfirevic, Andrew R Jones,[...]. Nucleic Acids Res 2015
532
14

First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.
Benjamin Young, Kathleen Squires, Parul Patel, Edwin Dejesus, Nicholaos Bellos, Daniel Berger, Denise H Sutherland-Phillips, Qiming Liao, Mark Shaefer, Paul Wannamaker. AIDS 2008
54
14

Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy.
Catrin O Plumpton, Vincent L M Yip, Ana Alfirevic, Anthony G Marson, Munir Pirmohamed, Dyfrig A Hughes. Epilepsia 2015
40
14

Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir.
S Hetherington, S McGuirk, G Powell, A Cutrell, O Naderer, B Spreen, S Lafon, G Pearce, H Steel. Clin Ther 2001
298
14

Hypersensitivity reactions to HIV therapy.
Mas Chaponda, Munir Pirmohamed. Br J Clin Pharmacol 2011
42
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.